OTIC - オトノミ― (Otonomy Inc.) オトノミ―

 OTICのチャート


 OTICの企業情報

symbol OTIC
会社名 Otonomy Inc (オトノミ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オトノミ(Otonomy Inc.)はバイオ医薬品会社である。同社は耳疾患・障害の治療薬の開発・製品化に従事する。同社の製品候補には、OTIPRIO、OTO-104、OTO-311がある。 OTIPRIOは、医師が投与する単回用量の抗菌剤であり、鼓膜瘻造設術(TTP)手術を受けた輸液による両側性中耳炎の小児患者の治療に使用され、商業的に購入することができる。OTO-104は、メニエール病および他の内耳状態の治療用の開発中のステロイドデキサメタゾンの持続曝露製剤である。OTO-311は、耳鳴りの治療用の開発中のN-メチル-D-アスパラギン酸(NMDA)受容体拮抗薬ガシクリジンの持続曝露製剤である。また、年齢関連の難聴(老人性難聴)などの感音難聴を対象とした他の多様な製品候補を有する。   オトノミ―は、米国の臨床段階のバイオ医薬品企業。耳の疾患および障害のための治療薬の開発と商業化に焦点を当てる。「AurionPro」は、鼓膜切開チュ―ブの配置手術時に中耳滲出の小児患者のための抗生物質シプロフロキサシン製剤、「OTO-104」は、メニエ―ル病患者の治療のためにステロイド・デキサメタゾンの製剤などを提供する。   Otonomy, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Ménière's disease; OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT); OTO-313 (gacyclidine) tinnitus; OTO-413 (BDNF) hidden hearing Loss; OTO-510 (otoprotectant) prevent CIHL; OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan in April 2008 and is headquartered in San Diego, CA.
本社所在地 4796 Executive Drive San Diego CA 92121 USA
代表者氏名 Jay Lichter ジェイ・ライヒター
代表者役職名 Independent Chairman of the Board
電話番号 +1 619-323-2200
設立年月日 39569
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.otonomy.com
nasdaq_url https://www.nasdaq.com/symbol/otic
adr_tso
EBITDA EBITDA(百万ドル) -64.93600
終値(lastsale) 2.75
時価総額(marketcap) 84232843.75
時価総額 時価総額(百万ドル) 79.63832
売上高 売上高(百万ドル) 0.97600
企業価値(EV) 企業価値(EV)(百万ドル) -20.36968
当期純利益 当期純利益(百万ドル) -64.80800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Otonomy Inc revenues decreased 38% to $424K. Net loss decreased 50% to $25M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative - other decrease of 65% to $7M (expense) Research and developme decrease of 51% to $11.5M (expense) Interest income increase of 24% to $763K (income).

 OTICのテクニカル分析


 OTICのニュース

   The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs  2020/08/19 11:32:33 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI ) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) DarioHealth Corp (NASDAQ: DRIO ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Otonomy Inc (NASDAQ: OTIC ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Pacira Biosciences Inc (NASDAQ: PCRX ) PDL BioPharma Inc (NASDAQ: PDLI ) Principia Biopharma Inc (NASDAQ: PRNB ) Qiagen NV (NYSE: QGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Silk Road Medical Inc (NASDAQ: SILK ) Syros Pharmaceuticals Inc (NASDAQ: SYRS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 18) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Interpace Biosciences Inc (NASDAQ: IDXG )(announced receipt of letters from recently departed employees regarding billing and compliance issues) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Poseida Therapeutics, Inc. (NASDAQ: PSTX )( announced clinical hold on its Phase 1 prostate cancer study) Predictive Oncology Inc (NASDAQ: POAI ) Recro Pharma Inc (NASDAQ: REPH ) Unity Biotechnology Inc (NASDAQ: UBX ) Stocks In Focus Venrock Reports Purchase of 451K Unum Shares Unum Therapeutics Inc (NASDAQ: UMRX ) shares advanced after Venrock Healthcare Partners III L.P. said in a filing it has purchased 451,000 shares of Unum's common stock in a series of transactions effected between Aug. 14 and Aug. 18, bringing the total number of shares owned by the fund to 4.355 million The stock climbed 16.24% to $3.15 in after-hours trading.
   Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update  2020/07/28 20:05:00 GlobeNewswire
Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020
   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 12:25:53 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioLife Solutions Inc (NASDAQ: BLFS ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunic Inc (NASDAQ: IMUX ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) ( reported forecast-beating second-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Novo Nordisk A/S (NYSE: NVO ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Otonomy Inc (NASDAQ: OTIC ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) Akouos Inc (NASDAQ: AKUS ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Nkarta Inc (NASDAQ: NKTX ) RENALYTIX AI ADR (NASDAQ: RNLX ) (went public Friday) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Midatech Terminates Sale Process, Strategic Review to Continue Midatech Pharma PLC-ADR (NASDAQ: MTP ), a drug delivery technology company, said it has terminated the formal sale process initiated in late April after it failed to receive any proposals from third parties.
   The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient  2020/07/17 11:41:01 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 16) AC Immune SA (NASDAQ: ACIU ) ( announced clinical trial update for its Alzheimer's vaccine candidate) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Dynavax Technologies Corporation (NASDAQ: DVAX )(announced a collaboration with Mt. Sinai to develop a universal influenza vaccine candidate with CpG1018 adjuvant) Heat Biologics Inc (NASDAQ: HTBX ) Novavax, Inc. (NASDAQ: NVAX ) Qiagen NV (NYSE: QGEN )( Thermo Fisher Scientific Inc. (NYSE: TMO ) announced a sweetened offer to buy the company) Quest Diagnostics Inc (NYSE: DGX ) Otonomy Inc (NASDAQ: OTIC ) Principia Biopharma Inc (NASDAQ: PRNB )(reacted to buyout rumors) Relay Therapeutics Inc (NASDAQ: RLAY ) (jumped 75.25% on its debut) Sanofi SA (NASDAQ: SNY ) (Bloomberg reported the French biotech is on a lookout to buy biotech companies, including Principia) TIZIANA LF SCIE/S ADR (NASDAQ: TLSA ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 16) Avidity Biosciences Inc (NASDAQ: RNA ) Legend Biotech Corp (NASDAQ: LEGN ) Nkarta Inc (NASDAQ: NKTX ) (IPOed last Friday) Repare Therapeutics Inc (NASDAQ: RPTX ) Tricida Inc (NASDAQ: TCDA ) ( received a letter from FDA citing deficiencies in its NDA for the approval of metabolic …
   ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO® (ciprofloxacin otic suspension), the First and Only Single-Dose Treatment for Acute Otitis Externa (Swimmer's Ear)  2020/06/17 14:23:00 PR Newswire
ROUND ROCK, Texas, June 17, 2020 /PRNewswire/ -- ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF) a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced today the signing of an exclusive agreement with Otonomy, a…
   The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs  2020/08/19 11:32:33 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI ) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) DarioHealth Corp (NASDAQ: DRIO ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Otonomy Inc (NASDAQ: OTIC ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Pacira Biosciences Inc (NASDAQ: PCRX ) PDL BioPharma Inc (NASDAQ: PDLI ) Principia Biopharma Inc (NASDAQ: PRNB ) Qiagen NV (NYSE: QGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Silk Road Medical Inc (NASDAQ: SILK ) Syros Pharmaceuticals Inc (NASDAQ: SYRS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 18) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Interpace Biosciences Inc (NASDAQ: IDXG )(announced receipt of letters from recently departed employees regarding billing and compliance issues) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Poseida Therapeutics, Inc. (NASDAQ: PSTX )( announced clinical hold on its Phase 1 prostate cancer study) Predictive Oncology Inc (NASDAQ: POAI ) Recro Pharma Inc (NASDAQ: REPH ) Unity Biotechnology Inc (NASDAQ: UBX ) Stocks In Focus Venrock Reports Purchase of 451K Unum Shares Unum Therapeutics Inc (NASDAQ: UMRX ) shares advanced after Venrock Healthcare Partners III L.P. said in a filing it has purchased 451,000 shares of Unum's common stock in a series of transactions effected between Aug. 14 and Aug. 18, bringing the total number of shares owned by the fund to 4.355 million The stock climbed 16.24% to $3.15 in after-hours trading.
   Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update  2020/07/28 20:05:00 GlobeNewswire
Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020
   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 12:25:53 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioLife Solutions Inc (NASDAQ: BLFS ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunic Inc (NASDAQ: IMUX ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) ( reported forecast-beating second-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Novo Nordisk A/S (NYSE: NVO ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Otonomy Inc (NASDAQ: OTIC ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) Akouos Inc (NASDAQ: AKUS ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Nkarta Inc (NASDAQ: NKTX ) RENALYTIX AI ADR (NASDAQ: RNLX ) (went public Friday) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Midatech Terminates Sale Process, Strategic Review to Continue Midatech Pharma PLC-ADR (NASDAQ: MTP ), a drug delivery technology company, said it has terminated the formal sale process initiated in late April after it failed to receive any proposals from third parties.
   The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient  2020/07/17 11:41:01 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 16) AC Immune SA (NASDAQ: ACIU ) ( announced clinical trial update for its Alzheimer's vaccine candidate) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Dynavax Technologies Corporation (NASDAQ: DVAX )(announced a collaboration with Mt. Sinai to develop a universal influenza vaccine candidate with CpG1018 adjuvant) Heat Biologics Inc (NASDAQ: HTBX ) Novavax, Inc. (NASDAQ: NVAX ) Qiagen NV (NYSE: QGEN )( Thermo Fisher Scientific Inc. (NYSE: TMO ) announced a sweetened offer to buy the company) Quest Diagnostics Inc (NYSE: DGX ) Otonomy Inc (NASDAQ: OTIC ) Principia Biopharma Inc (NASDAQ: PRNB )(reacted to buyout rumors) Relay Therapeutics Inc (NASDAQ: RLAY ) (jumped 75.25% on its debut) Sanofi SA (NASDAQ: SNY ) (Bloomberg reported the French biotech is on a lookout to buy biotech companies, including Principia) TIZIANA LF SCIE/S ADR (NASDAQ: TLSA ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 16) Avidity Biosciences Inc (NASDAQ: RNA ) Legend Biotech Corp (NASDAQ: LEGN ) Nkarta Inc (NASDAQ: NKTX ) (IPOed last Friday) Repare Therapeutics Inc (NASDAQ: RPTX ) Tricida Inc (NASDAQ: TCDA ) ( received a letter from FDA citing deficiencies in its NDA for the approval of metabolic …
   ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO® (ciprofloxacin otic suspension), the First and Only Single-Dose Treatment for Acute Otitis Externa (Swimmer's Ear)  2020/06/17 14:23:00 PR Newswire
ROUND ROCK, Texas, June 17, 2020 /PRNewswire/ -- ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF) a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced today the signing of an exclusive agreement with Otonomy, a…
   ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO® (ciprofloxacin otic suspension), the First and Only Single-Dose Treatment for Acute Otitis Externa (Swimmer's Ear)  2020/06/17 14:23:00 PR Newswire
ROUND ROCK, Texas, June 17, 2020 /PRNewswire/ -- ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF) a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced today the signing of an exclusive agreement with Otonomy, a…
   Otonomy to Host Pipeline Program Update Conference Call and Webcast  2020/06/08 11:30:00 GlobeNewswire
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative…
   Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update  2020/05/07 11:30:00 GlobeNewswire
Conference call to review status of clinical trials and timing to results to be held in June
   Tunisia-coronavirus: speculators lining their pockets, while Tunisians go hungry!  2020/04/03 19:26:11 African Manager
The fight against the spread of the coronavirus in Tunisia has brought with it the fight against one of the most deeply rooted phenomena, and which poisons the commercial practice in the country: It is obviously speculation! Tunisian economists generally consider that the phenomenon of speculation in Tunisia is a real “destabilizer” of the national economy, already weakened for years, and that it also generates very negative impacts on the purchasing power of Tunisians, which deteriorates from one day to the next. There is talk of a real shortage of semolina and flour. This is at least what has been observed in small commercial premises and large food stores… Moreover, the Tunisian Organization for Consumer Information (OTIC) has sent out a cry of distress and called on the government to immediately combat speculation given that several regions in the interior of the country are suffering from a shortage of flour and semolina, particularly in the governorates of Kasserine, Gafsa, Médenine and Tataouine.
   Reduction in fuel subsidy behind increase in product prices  2020/01/12 16:57:59 African Manager
Tunisians and civil society activists have reiterated, in recent days, their discontent after a 30% increase were recorded in some food prices such as salt, coffee, tea (…). These products are generally sold mainly in many hypermarkets. Contacted on Thursday, January 9, 2020 by AfricanManager, president of the Tunisian Organization for Consumer Information (OTIC) Lotfi Riahi said this is a dangerous overrun threatening the purchasing power of the Tunisian. He also reported that his organization had called on the Ministry of Commerce to set a profit margin to combat the dizzying increase in these and other products. “This 30% increase is unacceptable. A large majority of hypermarkets have been carrying out updating operations lately, under the pretext that prices are free, and that the Commerce Department has no right to intervene, except for the setting of the profit margin. We also found that many Tunisian consumers are unaware of this recent increase. We must put an end to this kind of abuse,” he said.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オトノミ― OTIC Otonomy Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)